title: Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus.
abstract: OBJECTIVE
  To compare differences in long-term outcome between adults with childhood-onset (age at diagnosis <18 years) systemic lupus erythematosus (SLE) and with adult-onset SLE.
  
  
  METHODS
  Data were derived from the University of California Lupus Outcomes Study, a longitudinal cohort of 885 adult subjects with SLE (90 childhood-onset [cSLE], 795 adult-onset [aSLE]). Baseline and 1-year followup data were obtained via structured 1-hour telephone interviews conducted between 2002 and 2006. Using self-report data, differences in organ involvement and disease morbidity, current disease status and activity, past and current medication use, and number of physician visits were compared, based on age at diagnosis of SLE.
  
  
  RESULTS
  Average disease duration for the cSLE and aSLE subgroups was 16.5 and 13.4 years, respectively, and mean age at followup was 30.5 and 49.9 years, respectively. When compared with aSLE subjects, cSLE subjects had a higher frequency of SLE-related renal disease, whereas aSLE subjects were more likely to report a history of pulmonary disease. Rates of clotting disorders, seizures, and myocardial infarction were similar between the 2 groups. At followup, cSLE subjects had lower overall disease activity, but were more likely to be taking steroids and other immunosuppressive therapies. The total number of yearly physician visits was similar between the 2 groups, although cSLE subjects had a higher number of nephrology visits.
  
  
  CONCLUSIONS
  This study demonstrates important differences in the outcomes of patients with cSLE and aSLE, and provides important prognostic information about long-term SLE disease activity and treatment.
authors.affiliation: University of California, San Francisco, CA, USA. hersha@peds.ucsf.edu
authors.forename: Aimee O
authors.initials: AO
authors.lastname: Hersh
authors.forename: Emily
authors.initials: E
authors.lastname: von Scheven
authors.forename: Jinoos
authors.initials: J
authors.lastname: Yazdany
authors.forename: Pantelis
authors.initials: P
authors.lastname: Panopalis
authors.forename: Laura
authors.initials: L
authors.lastname: Trupin
authors.forename: Laura
authors.initials: L
authors.lastname: Julian
authors.forename: Patricia
authors.initials: P
authors.lastname: Katz
authors.forename: Lindsey A
authors.initials: LA
authors.lastname: Criswell
authors.forename: Edward
authors.initials: E
authors.lastname: Yelin
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001706:Biopsy; D000068579:Celecoxib; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D007783:Lactones / Q000627:therapeutic use; D008137:Longitudinal Studies; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011241:Prednisone / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D006886:Hydroxychloroquine; D000068579:Celecoxib; D011241:Prednisone